Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2002

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Metastatic Breast CancerNeoplasms, Breast
Interventions
DRUG

Investigational Cancer Drug

Trial Locations (30)

15213

GSK Investigational Site, Pittsburgh

21201

GSK Investigational Site, Baltimore

24153

GSK Investigational Site, Salem

27710

GSK Investigational Site, Durham

27834

GSK Investigational Site, Greenville

28602

GSK Investigational Site, Hickory

29210

GSK Investigational Site, Columbia

31405

GSK Investigational Site, Savannah

33324

GSK Investigational Site, Plantation

33901

GSK Investigational Site, Fort Myers

37203

GSK Investigational Site, Nashville

37205

GSK Investigational Site, Nashville

38104

GSK Investigational Site, Memphis

38120

GSK Investigational Site, Memphis

38138

GSK Investigational Site, Germantown

48073

GSK Investigational Site, Royal Oak

50309

GSK Investigational Site, Des Moines

52722

GSK Investigational Site, Bettendorf

58103

GSK Investigational Site, Fargo

59101

GSK Investigational Site, Billings

60068

GSK Investigational Site, Park Ridge

60076

GSK Investigational Site, Skokie

60077

GSK Investigational Site, Skokie

73112

GSK Investigational Site, Oklahoma City

74136

GSK Investigational Site, Tulsa

77025

GSK Investigational Site, Houston

90095

GSK Investigational Site, Los Angeles

91911

GSK Investigational Site, Chula Vista

92064

GSK Investigational Site, Poway

03106

GSK Investigational Site, Hooksett

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY